HSV-1-targeted CRISPR/Cas9 gene therapy (Editas Medicine)

N/A

Report date: 2025/08/27 17:52:06

Base Information

Drug NameHSV-1-targeted CRISPR/Cas9 gene therapy (Editas Medicine)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR > CRISPR-Cas9Cell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsKeratitis, Herpetic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEditas Medicine Inc

China Registration ClassN/A

Develop Information

Active CompaniesEditas Medicine Inc

Inactive CompaniesN/A

Active IndicationsKeratitis, Herpetic

Inactive IndicationsN/A

Other Information

ATC CodeN/A